The Aquila study could make Darzalex the first approved drug for smouldering multiple myeloma.

Yet more data validate B7-H3, and put MediLink in the deal-making frame.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.

The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.

Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.

The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.

Phase 3 development plans for BNT327 and ivonescimab start to diverge.